Prostate cancer risk assessment program: a 10-year update of cancer detection.
OBJECTIVE
Guidelines for screening men at high risk for prostate cancer remain under investigation. We report our 10-year cancer detection data from the Prostate Cancer Risk Assessment Program, a longitudinal screening program for men at high risk.


METHODS
Men between ages 35 and 69 years with a family history of prostate cancer, any black man regardless of family history or any patient with a known mutation in the BRCA 1 gene are eligible for the Prostate Cancer Risk Assessment Program and undergo longitudinal followup. Cancer detection, prostate cancer features and the predictive value of screening parameters were determined based on Prostate Cancer Risk Assessment Program biopsy criteria.


RESULTS
A total of 609 men were accrued to the Prostate Cancer Risk Assessment Program as of the end of June 2006, of whom 61.2% were black. Of all participants 19% underwent prostate biopsies. The prostate cancer incidence was 9.0%, more than 90% of prostate cancers were Gleason score 6 or higher and 22% were Gleason score 7 or higher. The majority were organ confined. Of men diagnosed with prostate cancer 20% had a prostate specific antigen of less than 2.5 ng/ml and a free prostate specific antigen of less than 25% with a normal digital rectal examination.


CONCLUSIONS
Our results support aggressive screening measures for men at high risk for prostate cancer. The majority of cancers detected were at a prostate specific antigen of less than 4.0 ng/ml with a fifth diagnosed at a prostate specific antigen of below 2.5 ng/ml. These cancers were intermediate to high grade and organ confined, indicating a greater likelihood of cure following local therapy in these men.
Giri
Veda N
VN
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19012, USA. Veda.Giri@fccc.edu
Beebe-Dimmer
Jennifer
J
Buyyounouski
Mark
M
Konski
Andre
A
Feigenberg
Steven J
SJ
Uzzo
Robert G
RG
Hanks
Gerald
G
Godwin
Andrew K
AK
Chen
David Y T
DY
Gordon
Robert
R
Cescon
Terrence
T
Raysor
Susan
S
Watkins-Bruner
Deborah
D
D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood; D001706:Biopsy; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008403:Mass Screening / Q000639:trends*; D008875:Middle Aged; D010414:Pennsylvania / Q000453:epidemiology; D015397:Program Evaluation; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000453:epidemiology; D012189:Retrospective Studies; D018570:Risk Assessment; D013997:Time Factors
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen